Member Info for ogm4

200,000 trade appearing of what looks like a buy. We could see more block buying soon.

News could be around the corner and no doubt with the recent bullish statements made by the CEO a lot of work is ongoing behind the scenes to progress towards completing license deals and further collaboration with partners.

Massive trades appearing just now

2x 2 million

Tim CEO again reiterated earlier this week there will be plenty of news flow announced later this year with a number of deals to be concluded, as such this is a clear hold and accumulate for me.

Proactive recap for this week:

https://x.com/proactive_UK/status/1892934138514067940

Here we go

Https://x.com/proactive_UK/status/1892912174818840631

Accumulated some more this morning

Lanstead significant holding increase to 16.13%

Https://x.com/tr1rns/status/1892902175577108874

Tim McCarthy CEO on Immupharma now being well funded for the next 1.5-2 years:

"We weren't particularly outlooking for money if I am honest, however... a very small number of very long standing shareholders made it known it would be useful to take some more onboard at this point that they would be prepared to back a fund raising..."

"We would not have taken another Lanstead arrangement unless we were absolutely confident of the news flow coming up this year ... and the effect that positive news flow we expect to have on the share price."

Strong statements by the CEO indicating positive news flow is to be expected later this year. Also interesting to hear that initially they were not looking for more funds, I guess also as result of the cost cutting efforts done over the last few years. All in all well funded with limited overhead.

IMM have set themselves up for a strong negotiation position for any potential future JV partnerships, P140 license deals or takeover imo.

Today will be interesting

Expecting a climb back to 5p

Another very confident interview by the CEO just released today only one month after the previous one.

Expecting a rich news flow over the coming weeks and months providing updates on P140 and ongoing talks with a number of pharmas.

Recent placing was oversubscribed in other words currently plenty of interest in Immupharma.

IMM is now well funded until the end of 2026.

Anticipating big developments this year.

New interview slowly trickling through now...

Plus there seems to be a lot of confidence by Immupharma recently on now being well funded for the next two years (at least until the end of 2026), also after having significantly cut down overhead costs.

"Being able to apply this new funding to the P140 program will deliver quicker results and also be a major contributor to regular positive news flow and program updates which will have a major impact to drive a positive upward movement in the share price, thereby increasing value for all shareholders."

It works both ways as the settlement is subject to adjustment upwards or downwards each month depending on the Company's share price at the time.

The Sharing Agreement provides the opportunity for the Company to benefit from positive future share price performance.

Tim McCarthy, CEO: “2025 will be a transformational year for IMM, with further positive news flow on P140 platform"

Fingers crossed

Big trades coming through now

"IMM confirms successful Lanstead Subscription and over subscribed placing to raise £2.91m. Tim McCarthy, CEO: “2025 will be a transformational year for IMM, with further positive news flow on P140 platform"

https://x.com/ImmuPharma/status/1889944438224593338

Https://x.com/proactive_UK/status/1889951156811477197

"Additional funding at this pivotal time will allow the management to invest further into the P140 platform. This in turn will strengthen the Company's negotiating position in ongoing licensing negotiations, as well as to contribute to general working capital requirements.

Being able to apply this new funding to the P140 program will deliver quicker results and also be a major contributor to regular positive news flow and program updates which will have a major impact to drive a positive upward movement in the share price, thereby increasing value for all shareholders."